drugset
drugset / Trial / NCT02224079

Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers

NCT02224079 ↗

Phase 1 Completed 100 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

Study to assess safety, tolerability and pharmacokinetics (PK) of single intravenous (i.v.) doses of BIIB 722 CL

Timeline

Start
2002-04
Primary completion
2002-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB 722 CL Unknown 1 mg Intravenous
Subject BIIB 722 CL Unknown 2.5 mg Intravenous
Subject BIIB 722 CL Unknown 5 mg Intravenous
Subject BIIB 722 CL Unknown 10 mg Intravenous
Subject BIIB 722 CL Unknown 15 mg Intravenous
Subject BIIB 722 CL Unknown 20 mg Intravenous
Subject BIIB 722 CL Unknown 25 mg Intravenous
Subject BIIB 722 CL Unknown 37.5 mg Intravenous
Subject BIIB 722 CL Unknown 50 mg Intravenous
Subject BIIB 722 CL Unknown 75 mg Intravenous
Subject BIIB 722 CL Unknown 100 mg Intravenous
Subject BIIB 722 CL Unknown 125 mg Intravenous
Subject BIIB 722 CL Unknown 150 mg Intravenous

Indications

No indication recorded.